Christopher Gibson
Angel Investor
Salt Lake City, United States
Christopher Gibson is a Series A investor in Salt Lake City focused on Biotechnology and Health Care. Christopher Gibson is based out of Salt Lake City, Utah, and is the Interim Executive Advisor, Co-Founder and Chairman of the Board of Directors of Recursion Pharmaceuticals. Christopher previously worked at Cure Hereditary Hemorrhagic Telangiectasia as a Member of the Board of Directors. Christopher Gibson attended the University of Utah.Christopher Gibson has been awarded the 2013 TEDMED Front Line Scholar.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Christopher Gibson invests in
Stages Christopher Gibson invests in
Countries Christopher Gibson invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.5M–$14M
- Series A
- $10M–$55M
Investment Focus
Industry
- Biotechnology 18 (64%)
- Health Care 12 (43%)
- Pharmaceutical 7 (25%)
- Artificial Intelligence 7 (25%)
- Medical 6 (21%)
Stage
- Series A 16 (57%)
- Seed 9 (32%)
- Series B 1 (4%)
- Series C 1 (4%)
- Venture - Series Unknown 1 (4%)
Country
- United States 20 (71%)
- United Kingdom 3 (11%)
- France 1 (4%)
- Germany 1 (4%)
- Switzerland 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Zanskar develops a predictive platform informed by massive data for discovering previously unknown geothermal resources. Its platform includes subsurface characterization technology and massive data sets, enhancing and reducing risk in the exploration of geothermal resources. | $115M / Series C / Jan 21, 2026 | ||
| Play Health offers a perimenopause care app with hormone testing and personalized health guidance for women. | Seed / Oct 21, 2025 | ||
| Dunia Innovation is a creating the world's first self-driving laboratory for electrocatalytic CO2 utilization, which will drastically accelerate catalyst research. | $11.5M / Venture - Series Unknown / Oct 23, 2024 | ||
| Leash Biosciences engages in machine learning to solve medicinal chemistry. | $9.3M / Seed / Apr 05, 2024 | ||
| Loyal is a veterinary biotechnology company that develops pharmaceutical therapies for dogs aimed at extending their healthy lifespan and delaying age-associated diseases. It researches and formulates drug candidates designed to address the biological mechanisms of aging in different dog populations, including senior and large-breed dogs, withproducts progressing through clinical and regulatory pathways. Loyal engages in clinical studies and collaborates with veterinary professionals to advance its therapeutic programs and share scientific insights with the broader field. The company publishes research summaries to support transparency and enable other practitioners to build on its findings. | $45M / Series B / Mar 21, 2024 | ||
| Using robust prediction algorithms and AI design recommendations, Cradle assists biologists in rapidly designing better proteins. Cradle gives you complete ownership of the intellectual property while maintaining the privacy and security of your sequences and data. | $24M / Series A / Nov 28, 2023 | ||
| Amenities is the healthcare industry's leading Digital Front Door and patient loyalty platform. We help healthcare providers to acquire new patients and upgrade them to members. Our all-in-one patient app works with most modern EMRs to: 1) register new users into a full EMR account in <30 seconds with full identity verification and noduplicates, 2) help those patients find care options and book appointments with simple, conversion-optimized workflows, 3) seamlessly integrates key patient portal and 3rd party functions (i.e., video visits, secure messaging, test results, and billing), and 4) upgrade patients to members with custom experiences and services offerings (i.e., for Medicare Advantage, concierge memberships, direct-to-employer, or direct primary care patients) | $6.3M / Series A / Sep 19, 2023 | ||
| Noetik is an AI-native biotechnology company. Noetik leverages in advanced machine learning methods to discover and develop cancer immunotherapies. | $14M / Seed / Sep 07, 2023 | ||
| Mendaera is a medtech startup that focuses on developing advanced healthcare technologies, particularly in robotics and diagnostic tools. Mendaera envisions digitizing clinical judgment and technical expertise to ensure that high-quality care is accessible to every patient, in every care facility. Their platform, currently in development,integrates robotics, AI, real-time imaging, and connectivity to enable medical interventions at scale. | $24M / Series A / Aug 17, 2023 | ||
| A-Alpha Bio provides cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio's product, AlphaSeq, is a revolutionary cell-based platform technology that will fundamentally change the way that proteininteractions are measured.A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. | $22.4M / Series A / Jul 25, 2023 | ||
| See all 28 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Christopher Gibson invest in?
Christopher Gibson invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Seed stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Christopher Gibson invest in?
Christopher Gibson typically joins rounds of $1.5M–$14M at Seed and $10M–$55M at Series A. These are whole funding-round sizes, not Christopher Gibson's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Christopher Gibson took part in.
How do I contact Christopher Gibson?
Public channels for Christopher Gibson include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Christopher Gibson last invest?
The most recent investment recorded for Christopher Gibson closed in Jan 2026. Shizune tracks 28 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
